Fig. 4 | British Journal of Cancer

Fig. 4

From: Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study

Fig. 4

AFP percent change from baseline by cycle. Medians of AFP percent changes from baseline were plotted every three cycles for patients from the ITT population with baseline AFP ≥ 1.5 ULN by treatment arm. a for all patients; b for patients with best overall response of CR/PR; c for patients with best overall response of CR/PR/SD; d for patients with best overall response of PD. aITT population with baseline AFP ≥ 1.5 ULN. *Indicates a statistical difference between the two groups by non-parametric Wilcoxon rank-sum tests. AFP alpha-fetoprotein, CR complete response, ITT intention to treat, NA not available, PD progressive disease, PR partial response, SD stable disease, Q1 lower quartile, Q3 upper quartile

Back to article page